http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 09 Sep 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Kairos+Pharma+to+Present+at+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/27039476.html <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. </p><p> <b>Presentation Date:</b> September 14, 2026 </p><p> <b>Time:</b> 4:00 PM Eastern Time (Holmes 1) </p><p> <b>Webcast Link:</b> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjourney.ct.events%2Fview%2Feda75be8-1a00-4c5f-a6cf-3f463d938f29&amp;esheet=54599079&amp;newsitemid=20260909429715&amp;lan=en-US&amp;anchor=Available+Here&amp;index=1&amp;md5=122dfbc1acfbc249a468e6d0996128bf" shape="rect">Available Here</a> </p><p> A webcast of the presentation can be accessed on the investor relations section of the Kairos Pharma website. A replay http://www.streetinsider.com/Press+Releases/Kairos+Pharma+to+Present+at+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/27039476.html Wed, 09 Sep 2026 08:00:00 -0400 KAPA http://www.streetinsider.com/Business+Wire/Kairos+Pharma+to+Present+at+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/27039476.html <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. </p><p> <b>Presentation Date:</b> September 14, 2026 </p><p> <b>Time:</b> 4:00 PM Eastern Time (Holmes 1) </p><p> <b>Webcast Link:</b> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjourney.ct.events%2Fview%2Feda75be8-1a00-4c5f-a6cf-3f463d938f29&amp;esheet=54599079&amp;newsitemid=20260909429715&amp;lan=en-US&amp;anchor=Available+Here&amp;index=1&amp;md5=122dfbc1acfbc249a468e6d0996128bf" shape="rect">Available Here</a> </p><p> A webcast of the presentation can be accessed on the investor relations section of the Kairos Pharma website. A replay http://www.streetinsider.com/Business+Wire/Kairos+Pharma+to+Present+at+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/27039476.html Wed, 09 Sep 2026 08:00:00 -0400 KAPA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Aug+21/26961810.html si-local-file:///var/storage/secattach/20260821/26961810.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Aug+21/26961810.html Fri, 21 Aug 2026 16:31:00 -0400 KAPA O.67432597 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Aug+21/26961810.html si-local-file:///var/storage/secattach/20260821/26961810.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Aug+21/26961810.html Fri, 21 Aug 2026 16:31:00 -0400 KAPA O.67432597 http://www.streetinsider.com/Stock+Splits/Kairos+Pharma+announces+1-for-7+reverse+stock+split/26961768.html <p>Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced a 1-for-7 reverse stock split of its outstanding common shares, effective September 1, 2026 at 12:01 a.m. ET.</p> <p>Shares are expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026, under the existing ticker symbol "KAPA" and a new CUSIP number of 48301N203.</p> <p>Under the terms of the split, every seven shares of common stock will be automatically reclassified and combined into one share. No fractional shares will be issued; instead, holders entitled to a fraction will have their shares rounded up http://www.streetinsider.com/Stock+Splits/Kairos+Pharma+announces+1-for-7+reverse+stock+split/26961768.html Fri, 21 Aug 2026 16:30:15 -0400 A.23164265 KAPA O.01114765 O.67432597 http://www.streetinsider.com/Stock+Splits/Kairos+Pharma+announces+1-for-7+reverse+stock+split/26961768.html <p>Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced a 1-for-7 reverse stock split of its outstanding common shares, effective September 1, 2026 at 12:01 a.m. ET.</p> <p>Shares are expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026, under the existing ticker symbol "KAPA" and a new CUSIP number of 48301N203.</p> <p>Under the terms of the split, every seven shares of common stock will be automatically reclassified and combined into one share. No fractional shares will be issued; instead, holders entitled to a fraction will have their shares rounded up http://www.streetinsider.com/Stock+Splits/Kairos+Pharma+announces+1-for-7+reverse+stock+split/26961768.html Fri, 21 Aug 2026 16:30:15 -0400 A.23164265 KAPA O.01114765 O.67432597 http://www.streetinsider.com/Stock+Splits/Kairos+Pharma+announces+1-for-7+reverse+stock+split/26961768.html <p>Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced a 1-for-7 reverse stock split of its outstanding common shares, effective September 1, 2026 at 12:01 a.m. ET.</p> <p>Shares are expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026, under the existing ticker symbol "KAPA" and a new CUSIP number of 48301N203.</p> <p>Under the terms of the split, every seven shares of common stock will be automatically reclassified and combined into one share. No fractional shares will be issued; instead, holders entitled to a fraction will have their shares rounded up http://www.streetinsider.com/Stock+Splits/Kairos+Pharma+announces+1-for-7+reverse+stock+split/26961768.html Fri, 21 Aug 2026 16:30:15 -0400 A.23164265 KAPA O.01114765 O.67432597 http://www.streetinsider.com/Stock+Splits/Kairos+Pharma+announces+1-for-7+reverse+stock+split/26961768.html <p>Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced a 1-for-7 reverse stock split of its outstanding common shares, effective September 1, 2026 at 12:01 a.m. ET.</p> <p>Shares are expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026, under the existing ticker symbol "KAPA" and a new CUSIP number of 48301N203.</p> <p>Under the terms of the split, every seven shares of common stock will be automatically reclassified and combined into one share. No fractional shares will be issued; instead, holders entitled to a fraction will have their shares rounded up http://www.streetinsider.com/Stock+Splits/Kairos+Pharma+announces+1-for-7+reverse+stock+split/26961768.html Fri, 21 Aug 2026 16:30:15 -0400 A.23164265 KAPA O.01114765 O.67432597 http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the “Effective Time”), with shares expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026 under the existing trading symbol “KAPA” and a new CUSIP number http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html Fri, 21 Aug 2026 16:30:00 -0400 A.23164265 KAPA O.01114765 O.67432597 http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the “Effective Time”), with shares expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026 under the existing trading symbol “KAPA” and a new CUSIP number http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html Fri, 21 Aug 2026 16:30:00 -0400 A.23164265 KAPA O.01114765 O.67432597 http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the “Effective Time”), with shares expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026 under the existing trading symbol “KAPA” and a new CUSIP number http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html Fri, 21 Aug 2026 16:30:00 -0400 A.23164265 KAPA O.01114765 O.67432597 http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the “Effective Time”), with shares expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026 under the existing trading symbol “KAPA” and a new CUSIP number http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html Fri, 21 Aug 2026 16:30:00 -0400 A.23164265 KAPA O.01114765 O.67432597 http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the “Effective Time”), with shares expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026 under the existing trading symbol “KAPA” and a new CUSIP number http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html Fri, 21 Aug 2026 16:30:00 -0400 A.23164265 KAPA O.01114765 O.67432597 http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the “Effective Time”), with shares expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026 under the existing trading symbol “KAPA” and a new CUSIP number http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html Fri, 21 Aug 2026 16:30:00 -0400 A.23164265 KAPA O.01114765 O.67432597 http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the “Effective Time”), with shares expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026 under the existing trading symbol “KAPA” and a new CUSIP number http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html Fri, 21 Aug 2026 16:30:00 -0400 A.23164265 KAPA O.01114765 O.67432597 http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the “Effective Time”), with shares expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026 under the existing trading symbol “KAPA” and a new CUSIP number http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+1-for-7+Reverse+Stock+Split/26961758.html Fri, 21 Aug 2026 16:30:00 -0400 A.23164265 KAPA O.01114765 O.67432597 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Jun+30/26912943.html si-local-file:///var/storage/secattach/20260812/26912943.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Jun+30/26912943.html Wed, 12 Aug 2026 16:11:00 -0400 KAPA O.67432597 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Jun+30/26912943.html si-local-file:///var/storage/secattach/20260812/26912943.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Jun+30/26912943.html Wed, 12 Aug 2026 16:11:00 -0400 KAPA O.67432597 http://www.streetinsider.com/Corporate+News/Kairos+Pharma+to+test+cancer+drug+combo+with+Bayer%27s+Xofigo/26798866.html <p>Kairos Pharma, Ltd. (NYSE American: KAPA) announced a collaboration with Bayer to evaluate its antibody ENV-105 (carotuximab) in combination with Bayer's Xofigo (radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) involving bone.</p> <p>ENV-105 is described by the company as a CD105/BMP signaling inhibitor. Kairos Pharma is currently running a Phase 1 trial of ENV-105 in non-small cell lung cancer and a Phase 2 trial in castration-resistant prostate cancer. Interim data from the Phase 2 trial, presented at the 2025 ESMO Congress in Berlin, showed a median progression-free survival of more than 13 months and an 86% clinical benefit http://www.streetinsider.com/Corporate+News/Kairos+Pharma+to+test+cancer+drug+combo+with+Bayer%27s+Xofigo/26798866.html Wed, 22 Jul 2026 08:35:10 -0400 KAPA O.67432597 http://www.streetinsider.com/Corporate+News/Kairos+Pharma+to+test+cancer+drug+combo+with+Bayer%27s+Xofigo/26798866.html <p>Kairos Pharma, Ltd. (NYSE American: KAPA) announced a collaboration with Bayer to evaluate its antibody ENV-105 (carotuximab) in combination with Bayer's Xofigo (radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) involving bone.</p> <p>ENV-105 is described by the company as a CD105/BMP signaling inhibitor. Kairos Pharma is currently running a Phase 1 trial of ENV-105 in non-small cell lung cancer and a Phase 2 trial in castration-resistant prostate cancer. Interim data from the Phase 2 trial, presented at the 2025 ESMO Congress in Berlin, showed a median progression-free survival of more than 13 months and an 86% clinical benefit http://www.streetinsider.com/Corporate+News/Kairos+Pharma+to+test+cancer+drug+combo+with+Bayer%27s+Xofigo/26798866.html Wed, 22 Jul 2026 08:35:10 -0400 KAPA O.67432597 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Jul+16/26798871.html si-local-file:///var/storage/secattach/20260722/26798871.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Jul+16/26798871.html Wed, 22 Jul 2026 08:35:00 -0400 KAPA O.67432597 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Jul+16/26798871.html si-local-file:///var/storage/secattach/20260722/26798871.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Jul+16/26798871.html Wed, 22 Jul 2026 08:35:00 -0400 KAPA O.67432597 http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+Strategic+Collaboration+with+Bayer+to+Enhance+XOFIGO+Activity+in+Metastatic+Prostate+Cancer/26798859.html <p> <i>Combination Targets a $570M–$1.3B Addressable Global Market; ENV-105 Phase 2 Data Show 86% Clinical Benefit Rate in Resistant mCRPC</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer’s XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) involving bone. </p><p> Kairos Pharma’s current programs with ENV-105 include a Phase 1 trial in EGFR-driven non-small cell lung cancer and a Phase 2 trial for castrate resistant prostate http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+Strategic+Collaboration+with+Bayer+to+Enhance+XOFIGO+Activity+in+Metastatic+Prostate+Cancer/26798859.html Wed, 22 Jul 2026 08:35:00 -0400 KAPA O.67432597 http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+Strategic+Collaboration+with+Bayer+to+Enhance+XOFIGO+Activity+in+Metastatic+Prostate+Cancer/26798859.html <p> <i>Combination Targets a $570M–$1.3B Addressable Global Market; ENV-105 Phase 2 Data Show 86% Clinical Benefit Rate in Resistant mCRPC</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer’s XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) involving bone. </p><p> Kairos Pharma’s current programs with ENV-105 include a Phase 1 trial in EGFR-driven non-small cell lung cancer and a Phase 2 trial for castrate resistant prostate http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+Strategic+Collaboration+with+Bayer+to+Enhance+XOFIGO+Activity+in+Metastatic+Prostate+Cancer/26798859.html Wed, 22 Jul 2026 08:35:00 -0400 KAPA O.67432597 http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+Strategic+Collaboration+with+Bayer+to+Enhance+XOFIGO+Activity+in+Metastatic+Prostate+Cancer/26798859.html <p> <i>Combination Targets a $570M–$1.3B Addressable Global Market; ENV-105 Phase 2 Data Show 86% Clinical Benefit Rate in Resistant mCRPC</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer’s XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) involving bone. </p><p> Kairos Pharma’s current programs with ENV-105 include a Phase 1 trial in EGFR-driven non-small cell lung cancer and a Phase 2 trial for castrate resistant prostate http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+Strategic+Collaboration+with+Bayer+to+Enhance+XOFIGO+Activity+in+Metastatic+Prostate+Cancer/26798859.html Wed, 22 Jul 2026 08:35:00 -0400 KAPA O.67432597